HIV Vaccine
"Clinical, Immunologic, and Virologic Observations Related to Human Immunodeficiency Virus (HIV) Type I Infection in a Volunteer in an HIV-1 Vaccine Clinical Trial."
Published in Vaccine Weekly, June 12th, 1995
According to the authors' abstract of an article published in Journal of Infectious Diseases, "A vaccine breakthrough occurred in a phase 1 clinical trial of a human immunodeficiency virus (HIV) type 1 candidate subunit vaccine. The vaccine antigen, gp120(SF2), is a fully glycosylated protein produced in mammalian cells from the HIVSF2 isolate. After 4 immunizations, the subject developed neutralizing antibodies and lymphoproliferative responses to the gp120 protein. About 18 weeks after the last immunization, the subject became HIV infected. During the acute phase of infection, there was high virus burden, a decline in CD4+ T lymphocytes, increases in rgp120(SF2)-binding...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (1995-06-12)
More Articles from Vaccine Weekly
- Pneumococcal
Large Trial of Vaccine Efficacy in HIV+ Needed - Cancer/Vaccine
Research Focuses on Tumor-Unique Protein Segments - DNA Immunization
Particle-Mediated DNA Delivery to Skin Has Many Advantages - Immunology
Concurrent TIG and Td Administration Affects Response - Immunology
Is HIV Motivated via gp120 Immunoglobulin-Like Domain? - Immunology
Model Can Track Vaccine Induced Hepatitis B Antibodies - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
